WASHINGTON - US drugmaker Eli Lilly on Wednesday announced its experimental Alzheimer's drug significantly slowed cognitive and functional decline, results hailed as "remarkable" by experts.
This follows a 27 percent reduction in decline found for Biogen and Eisai's lecanemab, which was also declared a blockbuster and was approved by the US in January. "We are extremely pleased that donanemab yielded positive clinical results with compelling statistical significance for people with Alzheimer's disease in this trial," said Daniel Skovronsky, Lilly's chief scientific and medical officer, in a statement.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more: